EE200100511A - Meetod neuroloogiliste või neuropsühhiaatriliste häirete käitluseks - Google Patents

Meetod neuroloogiliste või neuropsühhiaatriliste häirete käitluseks

Info

Publication number
EE200100511A
EE200100511A EEP200100511A EEP200100511A EE200100511A EE 200100511 A EE200100511 A EE 200100511A EE P200100511 A EEP200100511 A EE P200100511A EE P200100511 A EEP200100511 A EE P200100511A EE 200100511 A EE200100511 A EE 200100511A
Authority
EE
Estonia
Prior art keywords
neuropsychiatric disorders
treating neurological
neurological
treating
neuropsychiatric
Prior art date
Application number
EEP200100511A
Other languages
English (en)
Inventor
Lynn Willis Gregory
Original Assignee
Clarencew Pty. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/285,859 external-priority patent/US6310085B1/en
Application filed by Clarencew Pty. Ltd. filed Critical Clarencew Pty. Ltd.
Publication of EE200100511A publication Critical patent/EE200100511A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0618—Psychological treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Social Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Radiology & Medical Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
EEP200100511A 1996-10-04 2000-03-31 Meetod neuroloogiliste või neuropsühhiaatriliste häirete käitluseks EE200100511A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO2745A AUPO274596A0 (en) 1996-10-04 1996-10-04 Method for the treatment of neurological or neuropsychiatric disorders
US09/285,859 US6310085B1 (en) 1997-10-03 1999-04-02 Method for the treatment of neurological or neuropsychiatric disorders
PCT/AU2000/000275 WO2000059504A1 (en) 1996-10-04 2000-03-31 Method for the treatment of neurological or neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
EE200100511A true EE200100511A (et) 2002-12-16

Family

ID=37945448

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100511A EE200100511A (et) 1996-10-04 2000-03-31 Meetod neuroloogiliste või neuropsühhiaatriliste häirete käitluseks

Country Status (21)

Country Link
US (1) US20020068692A1 (et)
EP (2) EP0964679A4 (et)
JP (2) JP2001503394A (et)
CN (1) CN1345238A (et)
AU (3) AUPO274596A0 (et)
BG (1) BG106065A (et)
BR (1) BR0009524A (et)
CA (2) CA2267381A1 (et)
CZ (1) CZ20013487A3 (et)
EE (1) EE200100511A (et)
HU (1) HUP0200287A3 (et)
IL (1) IL145696A0 (et)
MA (1) MA25404A1 (et)
MX (1) MXPA01009963A (et)
NO (1) NO20014674D0 (et)
NZ (1) NZ515023A (et)
PL (1) PL350961A1 (et)
SK (1) SK13862001A3 (et)
TR (1) TR200102864T2 (et)
WO (2) WO1998015267A1 (et)
ZA (1) ZA200108592B (et)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
DE69942009D1 (de) 1998-10-15 2010-03-25 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
IL130171A (en) * 1999-05-27 2004-06-01 Neurim Pharma 1991 Melatonin for use in the prevention and treatment of tardive dyskinesia, pharmaceutical formulations comprising it and its use for the manufacture of medicaments
IL138825A (en) * 2000-10-03 2006-06-11 Neurim Pharma 1991 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
US7485443B2 (en) 2001-07-17 2009-02-03 Northwestern University Solid-phase reactions
US7303869B2 (en) 2001-07-17 2007-12-04 Northwestern University Solid-phase reactions
JP2005219511A (ja) * 2002-02-05 2005-08-18 Azumaya:Kk ハイジャク防止システムおよぴ防止方法
CA2592605C (en) 2004-12-27 2010-12-07 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US7622495B2 (en) * 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
GB0701970D0 (en) 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
KR101760139B1 (ko) * 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
CA2834735C (en) * 2011-04-29 2021-06-01 University Of Medicine And Dentistry Of New Jersey Use of nalbuphine for treating dyskinesia
US10736889B2 (en) * 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US9918980B2 (en) * 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
CN103841890B (zh) 2011-05-31 2017-10-27 克拉伦苏股份有限公司 预防和治疗运动相关神经系统疾病的方法
KR20240024299A (ko) 2011-05-31 2024-02-23 포토파믹스 인코포레이티드 운동 관련 신경 상태들을 치료 및 진단하는 발광 장치들
GB201416017D0 (en) 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
CN116354924B (zh) * 2021-12-27 2025-05-30 江苏恩华药业股份有限公司 一种2-咪唑酮衍生物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468391A (en) * 1982-06-25 1984-08-28 Ayerst, Mckenna & Harrison, Inc. Combination of β-adrenoceptor antagonists and anxiolytic agents
IL79264A0 (en) * 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
US5283343A (en) * 1987-08-17 1994-02-01 Whitby Research, Inc. 2-aryl substituted N-acetyltryptamines and process of preparing such
US5093352A (en) * 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
JPH05500166A (ja) * 1989-09-15 1993-01-21 ドネツキ　ゴスダルストベンニ　メディツィンスキ　インスティテュト　イメニ　エム．ゴルコゴ 個体の感情状態を矯正するための装置
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5046494A (en) * 1990-08-27 1991-09-10 John Searfoss Phototherapy method
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GB2282807A (en) * 1993-10-15 1995-04-19 Merck & Co Inc Tryptophan esters and amides as tachykinin receptor antagonists
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
FR2778662B1 (fr) * 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
JP2001503394A (ja) 2001-03-13
CN1345238A (zh) 2002-04-17
SK13862001A3 (sk) 2003-04-01
NZ515023A (en) 2004-01-30
HUP0200287A3 (en) 2002-12-28
HUP0200287A2 (en) 2002-06-29
PL350961A1 (en) 2003-02-24
WO1998015267A1 (en) 1998-04-16
CA2267381A1 (en) 1998-04-16
CZ20013487A3 (cs) 2003-04-16
ZA200108592B (en) 2002-10-18
AUPO274596A0 (en) 1996-10-31
NO20014674L (no) 2001-09-26
MA25404A1 (fr) 2002-04-01
MXPA01009963A (es) 2003-07-14
NO20014674D0 (no) 2001-09-26
EP1189613A4 (en) 2004-02-11
CA2366850A1 (en) 2000-10-12
EP1189613A1 (en) 2002-03-27
EP0964679A1 (en) 1999-12-22
US20020068692A1 (en) 2002-06-06
BG106065A (en) 2002-04-30
AU782492B2 (en) 2005-08-04
TR200102864T2 (tr) 2002-03-21
AU736005B2 (en) 2001-07-26
IL145696A0 (en) 2002-06-30
JP2002541105A (ja) 2002-12-03
AU4372597A (en) 1998-05-05
EP0964679A4 (en) 2002-09-11
WO2000059504A1 (en) 2000-10-12
BR0009524A (pt) 2002-02-19
AU3410200A (en) 2000-10-23

Similar Documents

Publication Publication Date Title
HUP0001237A3 (en) Methods for treating vascular disorders
FI935922A7 (fi) Menetelmä jäteveden käsittelemiseksi
BR9602695A (pt) Composto método e composição para tratamento de distúrbios hiperproliferativos
IL145696A0 (en) Method for the treatment of neurological or neuropsychiatric disorders
NO984431D0 (no) FremgangsmÕte for behandling av smerte
NO991955L (no) FremgangsmÕte for behandling av hydrokarboner
NO961483D0 (no) Fremgangsmåte for behandling av oljeholdig formasjon
IL115809A0 (en) Method for treating anxiety
EP0729361A4 (en) METHOD FOR TREATING NEUROLOGICAL DISEASES
PL334012A1 (en) Novel method of treating the arthritis
EP0918767A4 (en) PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
ZA965346B (en) Methods of treating neuropeptide Y-associated conditions.
HUP9900138A3 (en) Method for treatment of wood element
EP0866702A4 (en) METHOD OF TREATMENT
EP0938296A4 (en) Method of treating alopecia
FR2755238B1 (fr) Procede de caracterisation d'un photorepeteur
FI973987L (fi) Menetelmä kognitiivisen toimintahäiriön hoitamiseksi
PL328925A1 (en) Method of treating bipolar disorders
ID16924A (id) Metode perlakuan poliolefin
EP0769904A4 (en) METHOD FOR TREATING ANXIETIES
EP0783304A4 (en) METHOD FOR TREATING FEELINGS
GB2294880B (en) Method of treating turf
GB9415902D0 (en) Method of treatment
MD676F1 (ro) Metoda de tratament al rinosinuzitelor Method for treatment of the rhinosinusitis
HK1025505A (en) Method for the treatment of neurological or neuropsychiatric disorders